Discover
GRCE
Grace Therapeutics, Inc.
2.11
2 x 1.59
2 x 2.88
bid
ask
-
0.02
0.94%
2 @ 07:30 PM
2.11 +0.00 (0.00%)
| Ytd | -39.02% | |
| 1y | -32.37% |
2.10
day range
2.17
2.07
52 week range
5.13
| Open | 2.14 | Prev Close | 2.13 | Low | 2.10 | High | 2.17 | Mkt Cap | 44.39M |
| Vol | 83.72K | Avg Vol | 213.31K | EPS | -1.17 | P/E | N/A | Forward P/E | -2.90 |
| Beta | 1.51 | Short Ratio | 3.25 | Inst. Own | 21.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 06-20 | 50-d Avg | 2.22 | 200-d Avg | 3.04 | 1yr Est | 10.44 |
| Income Statement | |||
| Operating Expenses | 15.92M | ||
| Research and Development Expense | 697.00K | ||
| Selling, General and Administrative Expense | 1.69M | ||
| Operating Income | -15.92M | ||
| Net Income | -15.79M | ||
| Net Income Common Stock | -15.79M | ||
| Net Income Common Stock (USD) | -15.79M | ||
| Consolidated Income | -15.79M | ||
| Earnings per Basic Share | -0.91 | ||
| Earnings per Basic Share (USD) | -0.91 | ||
| Earnings per Diluted Share | -0.91 | ||
| Earning Before Interest & Taxes (EBIT) | -15.79M | ||
| Earning Before Interest & Taxes (USD) | -15.79M | ||
| Weighted Average Shares | 17.27M | ||
| Weighted Average Shares Diluted | 17.27M | ||
| Balance Sheet | |||
| Cash and Equivalents | 13.76M | ||
| Cash and Equivalents (USD) | 13.76M | ||
| Trade and Non-Trade Receivables | 20.00K | ||
| Current Assets | 14.33M | ||
| Property, Plant & Equipment Net | 7.00K | ||
| Total Assets | 50.07M | ||
| Current Liabilities | 1.25M | ||
| Total Liabilities | 1.86M | ||
| Accumulated Retained Earnings (Deficit) | -244.27M | ||
| Accumulated Other Comprehensive Income | -6.04M | ||
| Shareholders Equity | 48.21M | ||
| Shareholders Equity (USD) | 48.21M | ||
| Assets Non-Current | 35.74M | ||
| Goodwill and Intangible Assets | 35.73M | ||
| Liabilities Non-Current | 612.00K | ||
| Trade and Non-Trade Payables | 1.25M | ||
| Tax Liabilities | 612.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -3.22M | ||
| Net Cash Flow from Operations | -3.22M | ||
| Share Based Compensation | 105.00K | ||